Case 21- Psychoses and Anatomy Flashcards
The brain changes in Schizophrenia
Individuals with Schizophrenia have a smaller hippocampus, increased activity in this region
Temporal lobe and hormones
- Glutamatergic neurones feed into the hippocampus
- The GABAeric interneurones inhibit the pyramidal excitatory hippocampal neurones
- This creates highly regulated and controlled output to the ventral tegmental area (VTA)
- The VTA is the origin of mesolimbic and mesocortical pathways
Temporal lobe in Schizophrenia
- The GABAergic neurones become damaged which is potentially the cause of the reduction in the size of the hippocampus
- This damage means that there is reduced inhibition and control in the area which may increase activity.
Physiology of the reward pathway
- Reward- involves activation of the VTA neurones and inhibition of activity of the n.accumbens output neurones
- VTA-accumbens dopamine neurones- driven by glutamate (AMPA-R, NMDA-R) and acetylcholine (nicotinic ACH-R) its inhibited by GABA (GABA-A, GABA-B)
- D2 dopamine receptors are inhibitory, activating these receptors decrease the firing in the accumbens output
Other pathways in the temporal lobe- NMDA hypofunction
Glutamatergic neurons and GABAergic neurons are involved in controlling the level of activity of neuronal pathways in schizophrenia:
• NMDA receptor hypofunction- may reduce mesocortical dopamaminergic activity, decrease in dopamine release in the prefrontal cortex causes negative symptoms
• NMDA may affect GABAergic interneurons- alters cortical processing, cognitive impairment
• NMDA hypofunction removes GABA inhibition of VTA- enhances dopamine release in mesolimbic area, causes positive symptoms
Dopamine
A biogenic amine neurotransmitter. Plays an important role in coordinating muscle movement. Involved in motivation, reward and reinforcement learning
Synthesis= Tyrosine -> Dihydroxyphenylalanine (DOPA) -> Dopamine
The 4 dopamine pathways- Mesocortical, Mesolimbic, Nigrostriatal, Tuberoinfundibular
Dopamine receptors and release
Dopamine has 5 receptors D1, D2, D3, D4 and D5 all of which are G-protein coupled receptors. Can have an intracellular or excitatory effect depending on the receptor. Its reabsorbed from the synaptic cleft via the dopamine active transporter (DAT) and recycled back into vesicles. Its broken down by catechol-O-methyltransferase and monoamine oxidase
Positive symptoms of schizophrenia
1) Agitation
2) Conceptual disorganisation
3) Delusions
4) Grandiosity
5) Hallucinations
6) Hostility, Paranoia, Suspician
Negative symptoms of schizophrenia
1) Apathy
2) Absent, blunted or incongurous emotional response
3) Reduction in speech
4) Social withdrawal
5) Impaired attention
6) Anhedonia
7) Sexual problems
8) Lethargy
Dopamine Mesocortical pathway
From the ventral tegmental area (VTA) to the Mesocortical area (Prefrontal cortex). The purpose of this pathway is cognition and mood/emotions. In Schitzophrenia underactivity of dopamine in this area results in negative symptoms like low energy and apathy
Dopamine Mesolimbic pathway
From the ventral tegmental area (VTA) to the mesolimbic area. Which is the ventral striatum of the basal ganglia in the forebrain. The purpose of this area is reward, addiction and sensory processing. In Schizophrenia overactivity/excess of dopamine in this region causes positive symptoms like hallucinations, delusions and disordered thoughts
Dopamine Nigrostriatal pathway
From the substantia nigra to the striatum. Its part of the extrapyramidal motor system and is involved in the initiation and control of movement. Parkinsons disease is caused by defects in the pathway when a loss of neurones in the substantia nigra causes a deficit of dopamine.
Dopamine Tuberoinfundibular pathway
Projects from the infundibular nucleus i.e. the arcuate nucleus in the hypothalamus to the anterior pituitary. Dopamine acts as prolactin release inhibiting factor (PRIF) which causes tonic inhibition of lactation by binding to dopamine D2 receptors. Some of the antipsychotic drugs exert their effects by binding to the dopamine D2 receptors which will result in an increase of prolactin which in turn can lead to galactorrhoea and gynaecomastia.
Noradrenaline/norepinephrine
A biogenic amine neurotransmitter. It projects predominantly to the forebrain region. Involved in sleep, wakefulness, arousal, attention as well as feeding behaviour
Synthesis= Tyrosine -> Dihydroxyphenylalanine (DOPA) -> Dopamine -> Norepinephrine
Pathways- goes to large areas of the brain, the Cerebellum, Cerebral cortex, Thalamus, Limbic system.
Purpose- arousal/wakefulness, attention, feeding behaviour
Noradrenaline/Norepinephrine- release, receptor binding, reabsorption
Release and receptor binding= It binds to ∝ and B adrenergic G-protein coupled receptors. It has an excitatory effect.
Reabsorption= Noradrenaline is reabsorbed via the norepinephrine transporter (NET). It is broken down by catechol-O-methyltransferase and monoamine oxidase.
Serotonine/5-hydroxytryptamine
It’s a biogenic amine neurotransmitter. Its primarily produced in neurons within the raphe nuclei which are found in the pons and brainstem. Its likely that every neurone in the brain receives serotonergic innervation. Regulates sleep and wakefulness. Interacts with the dopamine pathway.
Synthesis= Tryptophan -> 5-hydroxytryptophan -> 5-hydroxytryptamine
Serotonin- release, receptor binding and reabsorption
Release and receptor binding- It binds to G-protein coupled and ionotropic receptors There are 15 types of serotonin receptors and can have both inhibitory and excitatory effects.
Reabsorption= Serotonin is reabsorbed from the synaptic cleft by the 5-hydroxytryptamine transporter (5-HTT / SERT). Many antidepressant drugs are selective serotonin reuptake inhibitors. It is broken down by monoamine oxidase.
Serotonin- pathways, functions and clinical relevance
Pathways- starts at the raphe nuclei in the brainstem. There are connection to large areas of the brain Cerebellum, Cerebral cortex, Striatum (caudate putamen) and the Hippocampus.
Functions- controls arousal, sleep/wake cycle, mood behaviour, appetitive.
Clinical relevance- a serotonin deficit is implicated in the development of depression and anxiety.
Acetylcholine
Its an amino acid neurotransmitter. Is a neurotransmitter in the CNS as well as the skeletal neuromuscular junction. Acetylcholinesterase breaks down acetylcholine into acetate and choline. It has both excitatory and inhibitory effects. Choline is reabsorbed via the choline transporter (ChT)
Acetylcholine- two pathways
- Basal forebrain nuclei- large parts of the cortex, Thalamus, Amygdala, Hippocampus
- Dorsolateral pontine/tegmental region- Cerebellum, Spinal cord, Thalamus, Hypothalamus, Amygdala, Hippocampus
Glutamate
Its an amino acid neurotransmitter. It’s the main excitatory neurotransmitter in the CNS, about half of all brain synapses release glutamate. Excessive release of glutamate during trauma can cause excitotoxic brain damage. Doesn’t cross the blood brain barrier meaning its synthesised in the neurons from local precursors. The major receptors targeted by glutamate are the AMPA, NMDA and Kainate receptors.
Glutamate- synthesis, release, receptor binding, reabsorption
Synthesis= Glutamine -> Glutamate
Release and receptor binding- It binds to ionotropic AMPA, N-Methyl-D-aspartate (NMDA) and kainate G-protein coupled receptors. It is the main excitatory neurotransmitter.
It is reabsorbed by the excitatory amino acid transporters.